Jung et al.
12
|
Patients who had (a) cryptogenic stroke with advanced or
metastatic cancer at the time of stroke onset; and (b) elevated
D-dimer levels (>1.11 mg/mL) and/or diffusion-restricted
lesions in multiple vascular territories. |
Cho et al.
17
|
Patients (1) with any diagnosis of current or previous
metastatic disease, (2) undergoing current treatment for
malignancy, (3) who refused treatment for current cancer, (4)
who received first diagnosis of cancer during hospitalization
after the onset of stroke. |
Lee et al. 2019
13
|
Patients (1) with any metastatic disease, (2) undergoing current
treatment for a malignancy, (3) offered treatment for a
malignancy, but declined. |
Ozaki et al.
14
|
Patients (1) actively receiving treatment (such as radiation,
therapy or chemotherapy) for malignancy or (2) being treated
conservatively for current active malignancy. |
Lee et al. 2021
15
|
Patients (1) currently undergoing or refusing treatment for
malignancy, (2) with cancer diagnosed during hospitalization for
stroke. |
Ciolli et al.
16
|
Patients (1) with cancer diagnosis occurred within six months
before stroke, (2) treated for cancer within the previous six
months, or 3- with recurrent or metastatic cancer. |
Verschoof et al.
18
|
Patients with (1) cancer diagnosis within 12 months prior to
stroke, (2) metastatic disease, or (3) cancer treatment in the
last 30 days, (4) who declined cancer treatment. |